orforglipron vs Semaglutide (Wegovy)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
orforglipron · Foundayo
Marketed by Eli Lilly and partners
NCT05803421 · Phase 3 · completed
ACHIEVE-4 was a randomized, open-label, event-driven Phase 3 trial. It assigned 2,749 adults with type 2 diabetes, obesity or overweight and established cardiovascular or chronic kidney disease to oral orforglipron or injected insulin glargine once daily. The primary endpoint was time to the first major cardiovascular event, and orforglipron had to be shown non-inferior to insulin glargine, with the upper limit of the 95% confidence interval for the hazard ratio below 1.8. Over a median of 2 years, events occurred in 4.2% of orforglipron patients and 5.0% of insulin glargine patients (hazard ratio 0.84, 95% CI 0.59 to 1.20), so non-inferiority was shown and the trial met its primary endpoint. The figures come from the peer-reviewed paper in The Lancet.
Next expected readout: February 2027 · NCT06672549 (registry estimate)
Reported efficacy
Mean Percent Change from Baseline in Body Weight (Baseline, Week 72): Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001) (met)
Result source: NCT05872620
Semaglutide (Wegovy)
Marketed by Novo Nordisk
NCT03548935 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial of 1,961 participants. At week 68, mean body-weight change was -15.6% with semaglutide versus -2.8% with placebo, and the primary comparison was statistically significant (p<0.0001), supporting strong evidence for this clinical weight-loss endpoint.
Next expected readout: December 2026 · NCT05173714 (registry estimate)
Reported efficacy
Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801 (met)
Result source: NCT03574597
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | orforglipron | Semaglutide (Wegovy) |
|---|---|---|
| Body weight, % change | -7.9% vs -0.6%−7.3 vs placeboNCT0593138011 other results
| -19.5% vs -3.8%−15.7 vs placeboNCT0564670628 other results
|
| Weight loss of 5% or more | 58.3% vs 15%+43.3 vs placeboNCT0593138010 other results
| 87% vs 29.2%+57.8 vs placeboNCT050647351 other result
|
| Weight loss of 10% or more | 38.3% vs 3.3%+35 vs placeboNCT0593138010 other results
| 70.4% vs 9.2%+61.2 vs placeboNCT050647359 other results
|
| Waist circumference, change (cm) | -5.7 vs -0.1−5.6 vs placeboNCT0593138012 other results
| -7.5 vs -1−6.5 vs placeboNCT0357459735 other results
|
Body weight, % change
- orforglipron
- -7.9% vs -0.6%−7.3 vs placeboNCT05931380
11 other results
- -8.7% vs -0.6% NCT05931380
- -5.9% vs -0.6% NCT05931380
- -12.3% vs -2% NCT05051579
- -8.6% vs -2% NCT05051579
- -12.6% vs -2% NCT05051579
- -11.2% vs -2% NCT05051579
- -13.5% vs -2.3% NCT05051579
- -9.4% vs -2.3% NCT05051579
- -14.7% vs -2.3% NCT05051579
- -12.5% vs -2.3% NCT05051579
- -9.6% vs -2.5% NCT05872620
- Semaglutide (Wegovy)
- -19.5% vs -3.8%−15.7 vs placeboNCT05646706
28 other results
- -14.2% vs -2.5% NCT05064735
- -13.4% vs -1.9% NCT03811574
- -14.4% vs -2.7% NCT05040971
- -13.9% vs -2.5% NCT04788511
- -12.2% vs -2.2% NCT06041217
- -12.5% vs -3.6% NCT04251156
- -9.9% vs -1.9% NCT03811574
- -16.4% vs -2.6% NCT04998136
- -16.4% vs -2.7% NCT04998136
- -16.4% vs -6.4% NCT04074161
- -9.4% vs -0.9% NCT03574597
- -17.7% vs -5.4% NCT03548987
- -7.8% vs -6% NCT03611582
- -14.8% vs 2.3% NCT04102189
- -16.4% vs -1.6% NCT04074161
- -15.8% vs -3.3% NCT03693430
- -9.9% vs -7.2% NCT03552757
- -19.5% vs -16.4% NCT05646706
- -5.5% vs -3.1% NCT04969939
- -13.8% vs -2.3% NCT02453711
- -16.3% vs -2.3% NCT02453711
- -11.2% vs -2.3% NCT02453711
- -11.4% vs -2.3% NCT02453711
- -11.6% vs -2.3% NCT02453711
- -8.6% vs -2.3% NCT02453711
- -6.0% vs -2.3% NCT02453711
- -4.5% vs -0.2% NCT04779697
- -13.6% vs -7.4% NCT05579249
Weight loss of 5% or more
- orforglipron
- 58.3% vs 15%+43.3 vs placeboNCT05931380
10 other results
- 61.4% vs 15% NCT05931380
- 45.9% vs 15% NCT05931380
- 92.0% vs 24.0% NCT05051579
- 89.5% vs 22.9% NCT05051579
- 72% vs 24.0% NCT05051579
- 74.4% vs 22.9% NCT05051579
- 90.4% vs 24.0% NCT05051579
- 87.3% vs 22.9% NCT05051579
- 89.5% vs 24.0% NCT05051579
- 88.8% vs 22.9% NCT05051579
- Semaglutide (Wegovy)
- 87% vs 29.2%+57.8 vs placeboNCT05064735
1 other result
- 72.5% vs 17.7% NCT04102189
Weight loss of 10% or more
- orforglipron
- 38.3% vs 3.3%+35 vs placeboNCT05931380
10 other results
- 35.1% vs 3.3% NCT05931380
- 18.0% vs 3.3% NCT05931380
- 74.8% vs 8.8% NCT05051579
- 71.3% vs 2.3% NCT05051579
- 46.5% vs 8.8% NCT05051579
- 39.4% vs 2.3% NCT05051579
- 69.1% vs 8.8% NCT05051579
- 69.9% vs 2.3% NCT05051579
- 61.9% vs 8.8% NCT05051579
- 56.6% vs 2.3% NCT05051579
- Semaglutide (Wegovy)
- 70.4% vs 9.2%+61.2 vs placeboNCT05064735
9 other results
- 61.8% vs 8.1% NCT04102189
- 65.9% vs 9.5% NCT04788511
- 64.6% vs 10.1% NCT02453711
- 71.9% vs 10.1% NCT02453711
- 57.8% vs 10.1% NCT02453711
- 58.5% vs 10.1% NCT02453711
- 56.0% vs 10.1% NCT02453711
- 36.6% vs 10.1% NCT02453711
- 18.9% vs 10.1% NCT02453711
Waist circumference, change (cm)
- orforglipron
- -5.7 vs -0.1−5.6 vs placeboNCT05931380
12 other results
- -5.9 vs -0.1 NCT05931380
- -3.7 vs -0.1 NCT05931380
- -10.6 vs -4 NCT05051579
- -10.1 vs -3.6 NCT05051579
- -9.6 vs -4 NCT05051579
- -8 vs -3.6 NCT05051579
- -13.6 vs -4 NCT05051579
- -12.2 vs -3.6 NCT05051579
- -11.2 vs -4 NCT05051579
- -8.8 vs -3.6 NCT05051579
- -5.8 NCT06023095
- -11.7 NCT06023095
- Semaglutide (Wegovy)
- -7.5 vs -1−6.5 vs placeboNCT03574597
35 other results
- -14.1 vs -4.4 NCT03548935
- -6.9 vs 3.2 NCT03548987
- -9.7 vs -4.3 NCT03552757
- -15.2 vs -6.1 NCT03611582
- -18 vs -5.6 NCT05646706
- -13.3 vs -5.9 NCT05064735
- -12.7 vs -0.5 NCT04102189
- -13.6 vs -2 NCT04074161
- -11.2 vs -1.8 NCT03811574
- -10.2 vs -1.9 NCT03811574
- -11.6 vs -2.8 NCT05040971
- -12 vs -2.8 NCT04788511
- -14.3 vs -4.5 NCT03693430
- -9.1 vs -2.4 NCT06041217
- -11.1 vs -3.8 NCT04251156
- -15.2 vs -4.3 NCT03693430
- -7.8 vs -1.8 NCT03811574
- -7.6 vs -1.9 NCT03811574
- -12 vs -3 NCT04998136
- -4.8 vs -2.7 NCT04969939
- -12.3 vs -3.5 NCT02453711
- -14.9 vs -3.5 NCT02453711
- -10.9 vs -3.5 NCT02453711
- -11.1 vs -3.5 NCT02453711
- -11.0 vs -3.5 NCT02453711
- -8.8 vs -3.5 NCT02453711
- -6.1 vs -3.5 NCT02453711
- -18.2 vs -14.7 NCT05616013
- -21.3 vs -14.7 NCT05616013
- -15.8 vs -13.6 NCT05616013
- -19.0 vs -13.6 NCT05616013
- -15.6 vs -14.7 NCT05616013
- -18.1 vs -14.7 NCT05616013
- -14.6 vs -13.6 NCT05616013
- -16.6 vs -13.6 NCT05616013
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
8 other shared endpoints and safety
Coverage. orforglipron: 12 of 12 rows · Semaglutide (Wegovy): 12 of 12 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | orforglipron Rows use multiple source trials | Semaglutide (Wegovy) Rows use multiple source trials |
|---|---|---|
| BMI absolute change · kg | -2.63 vs -0.21 placebo kg @ 72wk36 mg QDa,b,c NCT05931380 · Phase 3 · registry result, not featured evidence show 2 more doses-2.83 vs -0.21 placebo kg @ 72wk12 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence -1.94 vs -0.21 placebo kg @ 72wk6 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence | -7.7 vs -1.5 placebo kg @ 72wk7.2 mgb,c NCT05646706 · Phase 3 · registry result, not featured evidence |
| Fasting Plasma Glucose absolute change · mmol/L | -0.5 vs NA placebo mmol/La,d,b,c,e NCT06023095 · Phase 1 · registry result, not featured evidence show 1 more dose-0.17 vs NA placebo mmol/L NCT06023095 · Phase 1 · registry result, not featured evidence | -0.5 vs 0.1 placebo mmol/L @ 104wk2.4 mga,d,b,c,e NCT03693430 · Phase 3 · registry result, not featured evidence show 1 more dose-0.46 vs 0.1 placebo mmol/L @ 104wk*2.4 mg NCT03693430 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -8.3 mg/dL as posted |
| HbA1c absolute change · percentage points | -1.66% vs -0.47% placebo @ 72wkorforglipron 17.2 mgf,c NCT05872620 · Phase 3 · sponsor-reported, not registry data 3 other source trials-0.61% (n=57) vs 0.041% (n=60) placebo @ 72wk12 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence -0.62% (n=60) vs 0.041% (n=60) placebo @ 72wk36 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence -0.53% (n=61) vs 0.041% (n=60) placebo @ 72wk6 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence | -0.3% (n=938) vs 0% (n=167) placebo @ 72wk7.2 mgf,c NCT05646706 · Phase 3 · registry result, not featured evidence |
| SBP absolute change · mmHg | -4.36 vs -0.055 placebo mmHg @ 72wk36 mg QDa,b,c NCT05931380 · Phase 3 · registry result, not featured evidence show 2 more doses-3.84 vs -0.055 placebo mmHg @ 72wk12 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence -5.08 vs -0.055 placebo mmHg @ 72wk6 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence | -10 vs -4 placebo mmHg @ 72wk7.2 mgb,c NCT05646706 · Phase 3 · registry result, not featured evidence |
| VAT Change Cm2 absolute change · cm | -49.3 vs -7.2 placebo cm @ 72wk36 mg QDa,b,c,g NCT05931380 · Phase 3 · registry result, not featured evidence show 2 more doses-52.3 vs -7.2 placebo cm @ 72wk12 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence -47.5 vs -7.2 placebo cm @ 72wk6 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence | -67.4 vs -13.8 placebo cm @ 68wk2.4 mga,b,c,g NCT03811574 · Phase 3 · registry result, not featured evidence show 1 more dose-41.7 vs -13.8 placebo cm @ 68wk1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence |
| Weight absolute change · kg | -14.2 vs -2.4 placebo kg @ 36wk36 mga,h,b,c,i NCT05051579 · Phase 2 · registry result, not featured evidence show 3 more doses-9.8 vs -2.4 placebo kg @ 36wk12 mg NCT05051579 · Phase 2 · registry result, not featured evidence -15.4 vs -2.4 placebo kg @ 36wk45 mg NCT05051579 · Phase 2 · registry result, not featured evidence -13.6 vs -2.4 placebo kg @ 36wk24 mg NCT05051579 · Phase 2 · registry result, not featured evidence | -16.9 vs -2.1 placebo kg @ 104wk2.4 mgh,b,c,i NCT03693430 · Phase 3 · registry result, not featured evidence |
| Weight Loss 15% responder rate · % of participants | 18.33% (n=60) vs 0% (n=60) placebo @ 72wk36 mg QDa,j,k,f,c,g NCT05931380 · Phase 3 · registry result, not featured evidence show 2 more doses22.81% (n=57) vs 0% (n=60) placebo @ 72wk12 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence 9.84% (n=61) vs 0% (n=60) placebo @ 72wk6 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence | 47.8% (n=253) vs 2.5% (n=120) placebo @ 68wk2.4 mgj,k,f,c,g Yes NCT05064735 · Phase 3 · registry result, not featured evidence 1 other source trial53.4% (n=131) vs 4.8% (n=62) placebo @ 68wk2.4 mg Yes NCT04102189 · Phase 3 · registry result, not featured evidence |
| Weight Loss 20% responder rate · % of participants | 8.33% (n=60) vs 0% (n=60) placebo @ 72wk36 mg QDa,j,k,f,c,g NCT05931380 · Phase 3 · registry result, not featured evidence show 2 more doses12.28% (n=57) vs 0% (n=60) placebo @ 72wk12 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence 3.28% (n=61) vs 0% (n=60) placebo @ 72wk6 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence | 23.3% (n=253) vs 0% (n=120) placebo @ 68wk2.4 mgj,k,f,c,g Yes NCT05064735 · Phase 3 · registry result, not featured evidence 1 other source trial37.4% (n=131) vs 3.2% (n=62) placebo @ 68wk2.4 mg Yes NCT04102189 · Phase 3 · registry result, not featured evidence |
| Dropout rate | 10%36 mg QDl NCT05931380 · Phase 3 · registry result, not featured evidence show 97 more results8.8%12 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence 11.5%6 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence —36 mg NCT05051579 · Phase 2 · registry result, not featured evidence —36 mg NCT05051579 · Phase 2 · registry result, not featured evidence 12%12 mg NCT05051579 · Phase 2 · registry result, not featured evidence —45 mg NCT05051579 · Phase 2 · registry result, not featured evidence —45 mg NCT05051579 · Phase 2 · registry result, not featured evidence 13.2%24 mg NCT05051579 · Phase 2 · registry result, not featured evidence —17.2 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —36 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —36 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —12 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —12 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —6 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —6 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —24 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —24 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —14.5 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —9 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —5.5 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —3 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —3 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —2.5 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —1 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —1 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —0.8 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 1) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 2) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 3) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 4) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 5) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 6) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 7) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 8) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 9) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 10) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 12) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 13) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 14) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 15) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 16) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 18) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 11) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 17) NCT06440980 · Phase 1 · registry result, not featured evidence 10%LY3502970 (Cohort 1) NCT06023095 · Phase 1 · registry result, not featured evidence 10%LY3502970 (Cohort 2) NCT06023095 · Phase 1 · registry result, not featured evidence —36 mg NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —12 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —12 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —6 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —6 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg + 0.2 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 0.25 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 1000 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 0.25 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —24 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —24 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —20 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —20 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —3 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —3 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —1 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —1 mg + 1000 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —1 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence —36 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence —36 mg DF capsule NCT05841238 · Phase 1 · registry result, not featured evidence —36 mg EPB capsule NCT05841238 · Phase 1 · registry result, not featured evidence —60 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —45 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —37.5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —37.5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —35 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —35 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —20 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —16 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence —10 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —8 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence —5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —2.5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —2 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence —0.8 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%LY3502970 Cohort 1 NCT05313802 · Phase 1 · registry result, not featured evidence 4.2%LY3502970 Cohort 2 NCT05313802 · Phase 1 · registry result, not featured evidence 8.3%LY3502970 Cohort 3 NCT05313802 · Phase 1 · registry result, not featured evidence | —2.4 mg weeklym NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 show 40 more results5.1%2.4 mg weekly NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 11%2.4 mg NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 —2.4 mg NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 3.2%2.4 mg NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 2.9% NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3 16.7%2.4 mg NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 15.3%Behavioral Treatment + Medication NCT05548647 · Phase 4 · registry result, not featured evidence · combination —Continued Medication (Semaglutide) NCT05548647 · Phase 4 · registry result, not featured evidence 14.4%2.4 mg NCT05579249 · Phase 4 · registry result, not featured evidence —2.4 mg NCT06041217 · Phase 3 · registry result, not featured evidence 0%2.4 mg NCT06041217 · Phase 3 · registry result, not featured evidence 4.6%7.2 mg NCT05646706 · Phase 3 · registry result, not featured evidence 0% NCT04998136 · Phase 3 · registry result, not featured evidence 9.2%2.4 mg NCT05064735 · Phase 3 · registry result, not featured evidence 7.2%2.4 mg NCT05040971 · Phase 3 · registry result, not featured evidence 2.7%2.4 mg NCT04788511 · Phase 3 · registry result, not featured evidence —2.4 mg NCT04251156 · Phase 3 · registry result, not featured evidence 2%2.4 mg NCT04251156 · Phase 3 · registry result, not featured evidence 1.5%2.4 mg NCT04102189 · Phase 3 · registry result, not featured evidence 4.8%2.4 mg NCT04074161 · Phase 3 · registry result, not featured evidence 2.6%2.4 mg NCT03693430 · Phase 3 · registry result, not featured evidence 2%2.4 mg NCT03811574 · Phase 3 · registry result, not featured evidence 2%1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence 33.9%30 mg/kg + 1.0 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 38.6%30 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 50%10 mg/kg + 1.0 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 37.5%10 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 12.5% NCT05302596 · Phase 2 · registry result, not featured evidence 0%2.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination —2.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination 0%1.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination —1.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination 2%0.4 mg NCT02453711 · Phase 2 · registry result, not featured evidence 2.9%0.4 mg (Fast Escalation) NCT02453711 · Phase 2 · registry result, not featured evidence 6.8%0.3 mg NCT02453711 · Phase 2 · registry result, not featured evidence 5.9%0.3 mg (Fast Escalation) NCT02453711 · Phase 2 · registry result, not featured evidence 8.7%0.2 mg NCT02453711 · Phase 2 · registry result, not featured evidence 6.9%0.1 mg NCT02453711 · Phase 2 · registry result, not featured evidence 10.7%0.05 mg NCT02453711 · Phase 2 · registry result, not featured evidence 10.4% NCT04779697 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | 3.3%36 mg QDl NCT05931380 · Phase 3 · registry result, not featured evidence show 97 more results3.5%12 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence 1.6%6 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence —36 mg NCT05051579 · Phase 2 · registry result, not featured evidence —36 mg NCT05051579 · Phase 2 · registry result, not featured evidence 4%12 mg NCT05051579 · Phase 2 · registry result, not featured evidence —45 mg NCT05051579 · Phase 2 · registry result, not featured evidence —45 mg NCT05051579 · Phase 2 · registry result, not featured evidence 1.9%24 mg NCT05051579 · Phase 2 · registry result, not featured evidence —17.2 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —36 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —36 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —12 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —12 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —6 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —6 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —24 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —24 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —14.5 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —9 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —5.5 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —3 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —3 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —2.5 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —1 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —1 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —0.8 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 1) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 2) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 3) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 4) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 5) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 6) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 7) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 8) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 9) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 10) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 12) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 13) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 14) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 15) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 16) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 18) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 11) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 17) NCT06440980 · Phase 1 · registry result, not featured evidence 0%LY3502970 (Cohort 1) NCT06023095 · Phase 1 · registry result, not featured evidence 10%LY3502970 (Cohort 2) NCT06023095 · Phase 1 · registry result, not featured evidence —36 mg NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —12 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —12 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —6 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —6 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg + 0.2 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 0.25 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 1000 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 0.25 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —24 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —24 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —20 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —20 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —3 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —3 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —1 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —1 mg + 1000 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —1 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence —36 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence —36 mg DF capsule NCT05841238 · Phase 1 · registry result, not featured evidence —36 mg EPB capsule NCT05841238 · Phase 1 · registry result, not featured evidence —60 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —45 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —37.5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —37.5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —35 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —35 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —20 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —16 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence —10 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —8 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence —5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —2.5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —2 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence —0.8 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%LY3502970 Cohort 1 NCT05313802 · Phase 1 · registry result, not featured evidence 4.2%LY3502970 Cohort 2 NCT05313802 · Phase 1 · registry result, not featured evidence 4.2%LY3502970 Cohort 3 NCT05313802 · Phase 1 · registry result, not featured evidence | —2.4 mg weeklym NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 show 40 more results—2.4 mg weekly NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 5.3%2.4 mg NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 —2.4 mg NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 —2.4 mg NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 — NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3 6.4%2.4 mg NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 —Behavioral Treatment + Medication NCT05548647 · Phase 4 · registry result, not featured evidence · combination —Continued Medication (Semaglutide) NCT05548647 · Phase 4 · registry result, not featured evidence —2.4 mg NCT05579249 · Phase 4 · registry result, not featured evidence —2.4 mg NCT06041217 · Phase 3 · registry result, not featured evidence —2.4 mg NCT06041217 · Phase 3 · registry result, not featured evidence —7.2 mg NCT05646706 · Phase 3 · registry result, not featured evidence — NCT04998136 · Phase 3 · registry result, not featured evidence —2.4 mg NCT05064735 · Phase 3 · registry result, not featured evidence —2.4 mg NCT05040971 · Phase 3 · registry result, not featured evidence —2.4 mg NCT04788511 · Phase 3 · registry result, not featured evidence —2.4 mg NCT04251156 · Phase 3 · registry result, not featured evidence —2.4 mg NCT04251156 · Phase 3 · registry result, not featured evidence —2.4 mg NCT04102189 · Phase 3 · registry result, not featured evidence —2.4 mg NCT04074161 · Phase 3 · registry result, not featured evidence —2.4 mg NCT03693430 · Phase 3 · registry result, not featured evidence —2.4 mg NCT03811574 · Phase 3 · registry result, not featured evidence —1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence 10.7%30 mg/kg + 1.0 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 1.8%30 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 14.3%10 mg/kg + 1.0 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 5.4%10 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 — NCT05302596 · Phase 2 · registry result, not featured evidence —2.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination —2.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination —1.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination —1.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination —0.4 mg NCT02453711 · Phase 2 · registry result, not featured evidence —0.4 mg (Fast Escalation) NCT02453711 · Phase 2 · registry result, not featured evidence —0.3 mg NCT02453711 · Phase 2 · registry result, not featured evidence —0.3 mg (Fast Escalation) NCT02453711 · Phase 2 · registry result, not featured evidence —0.2 mg NCT02453711 · Phase 2 · registry result, not featured evidence —0.1 mg NCT02453711 · Phase 2 · registry result, not featured evidence —0.05 mg NCT02453711 · Phase 2 · registry result, not featured evidence — NCT04779697 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 10%36 mg QDl NCT05931380 · Phase 3 · registry result, not featured evidence show 97 more results5.3%12 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence 1.6%6 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence 0%36 mg NCT05051579 · Phase 2 · registry result, not featured evidence 10.3%36 mg NCT05051579 · Phase 2 · registry result, not featured evidence 0%12 mg NCT05051579 · Phase 2 · registry result, not featured evidence 6.5%45 mg NCT05051579 · Phase 2 · registry result, not featured evidence 0%45 mg NCT05051579 · Phase 2 · registry result, not featured evidence 3.8%24 mg NCT05051579 · Phase 2 · registry result, not featured evidence 0%17.2 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%36 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0.6%36 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%12 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%12 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%6 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0.5%6 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%24 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%24 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%14.5 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%9 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence 0.5%5.5 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%3 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%3 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%2.5 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%1 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%1 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%0.8 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 1) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 2) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 3) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 4) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 5) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 6) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 7) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 8) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 9) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 10) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 12) NCT06440980 · Phase 1 · registry result, not featured evidence 2%tablet QD (dose level 13) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 14) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 15) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 16) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 18) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 11) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 17) NCT06440980 · Phase 1 · registry result, not featured evidence 0%LY3502970 (Cohort 1) NCT06023095 · Phase 1 · registry result, not featured evidence 0%LY3502970 (Cohort 2) NCT06023095 · Phase 1 · registry result, not featured evidence 0%36 mg NCT06186622 · Phase 1 · registry result, not featured evidence 0%36 mg NCT06186622 · Phase 1 · registry result, not featured evidence 0%36 mg NCT06186622 · Phase 1 · registry result, not featured evidence 0%36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%36 mg NCT06186622 · Phase 1 · registry result, not featured evidence 0%36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%12 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 5.3%12 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%6 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%6 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%36 mg + 0.2 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%36 mg + 0.25 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%36 mg + 1000 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%36 mg + 0.25 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%24 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%24 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%20 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%20 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%3 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%3 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%1 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%1 mg + 1000 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%1 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%36 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence 2.2%36 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence 0%36 mg DF capsule NCT05841238 · Phase 1 · registry result, not featured evidence 0%36 mg EPB capsule NCT05841238 · Phase 1 · registry result, not featured evidence 0%60 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%45 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%37.5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%37.5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%35 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%35 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 2.2%20 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%16 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence 0%10 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%8 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence 0%5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%2.5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%2 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence 0%0.8 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%LY3502970 Cohort 1 NCT05313802 · Phase 1 · registry result, not featured evidence 0%LY3502970 Cohort 2 NCT05313802 · Phase 1 · registry result, not featured evidence 0%LY3502970 Cohort 3 NCT05313802 · Phase 1 · registry result, not featured evidence | 9.8%2.4 mg weeklym NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 show 40 more results—2.4 mg weekly NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 —2.4 mg NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 7.7%2.4 mg NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 9.9%2.4 mg NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 33.4% NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3 9.1%2.4 mg NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 4.2%Behavioral Treatment + Medication NCT05548647 · Phase 4 · registry result, not featured evidence · combination 0%Continued Medication (Semaglutide) NCT05548647 · Phase 4 · registry result, not featured evidence 1.2%2.4 mg NCT05579249 · Phase 4 · registry result, not featured evidence 8.1%2.4 mg NCT06041217 · Phase 3 · registry result, not featured evidence —2.4 mg NCT06041217 · Phase 3 · registry result, not featured evidence 7.3%7.2 mg NCT05646706 · Phase 3 · registry result, not featured evidence 12.9% NCT04998136 · Phase 3 · registry result, not featured evidence 10%2.4 mg NCT05064735 · Phase 3 · registry result, not featured evidence 8.7%2.4 mg NCT05040971 · Phase 3 · registry result, not featured evidence 13.3%2.4 mg NCT04788511 · Phase 3 · registry result, not featured evidence 5.6%2.4 mg NCT04251156 · Phase 3 · registry result, not featured evidence —2.4 mg NCT04251156 · Phase 3 · registry result, not featured evidence 11.3%2.4 mg NCT04102189 · Phase 3 · registry result, not featured evidence 7.9%2.4 mg NCT04074161 · Phase 3 · registry result, not featured evidence 7.9%2.4 mg NCT03693430 · Phase 3 · registry result, not featured evidence 5%2.4 mg NCT03811574 · Phase 3 · registry result, not featured evidence 7%1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence 10.7%30 mg/kg + 1.0 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 12.7%30 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 12.5%10 mg/kg + 1.0 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 14.5%10 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 0% NCT05302596 · Phase 2 · registry result, not featured evidence 12.5%2.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination 0%2.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination 0%1.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination 4.3%1.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination 12.7%0.4 mg NCT02453711 · Phase 2 · registry result, not featured evidence 6.8%0.4 mg (Fast Escalation) NCT02453711 · Phase 2 · registry result, not featured evidence 5.8%0.3 mg NCT02453711 · Phase 2 · registry result, not featured evidence 5.9%0.3 mg (Fast Escalation) NCT02453711 · Phase 2 · registry result, not featured evidence 4.9%0.2 mg NCT02453711 · Phase 2 · registry result, not featured evidence 7.8%0.1 mg NCT02453711 · Phase 2 · registry result, not featured evidence 12.6%0.05 mg NCT02453711 · Phase 2 · registry result, not featured evidence 2.1% NCT04779697 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 36 mg QDl nausea 33.3% (placebo 0%) constipation 31.7% (placebo 8.3%) nasopharyngitis 20% (placebo 35%) NCT05931380 · Phase 3 · registry result, not featured evidence show 97 more results12 mg QD nasopharyngitis 42.1% (placebo 35%) constipation 28.1% (placebo 8.3%) nausea 15.8% (placebo 0%) NCT05931380 · Phase 3 · registry result, not featured evidence 6 mg QD constipation 36.1% (placebo 8.3%) nasopharyngitis 26.2% (placebo 35%) diarrhoea 14.8% (placebo 3.3%) NCT05931380 · Phase 3 · registry result, not featured evidence 36 mg nausea 41.4% (placebo 10%) constipation 27.6% (placebo 6%) vomiting 27.6% (placebo 6%) NCT05051579 · Phase 2 · registry result, not featured evidence 36 mg nausea 48.3% (placebo 10%) constipation 24.1% (placebo 6%) covid-19 24.1% (placebo 18%) NCT05051579 · Phase 2 · registry result, not featured evidence 12 mg nausea 50% (placebo 10%) vomiting 26% (placebo 6%) constipation 24% (placebo 6%) NCT05051579 · Phase 2 · registry result, not featured evidence 45 mg nausea 41.9% (placebo 10%) vomiting 29% (placebo 6%) constipation 19.4% (placebo 6%) NCT05051579 · Phase 2 · registry result, not featured evidence 45 mg nausea 36.7% (placebo 10%) diarrhoea 33.3% (placebo 10%) vomiting 26.7% (placebo 6%) NCT05051579 · Phase 2 · registry result, not featured evidence 24 mg nausea 58.5% (placebo 10%) diarrhoea 35.8% (placebo 10%) constipation 32.1% (placebo 6%) NCT05051579 · Phase 2 · registry result, not featured evidence 17.2 mg tablet QD vomiting 5.7% headache 3.4% nausea 3.4% NCT06440980 · Phase 1 · registry result, not featured evidence 36 mg capsule QD headache 6.7% constipation 4.4% dizziness 4.4% NCT06440980 · Phase 1 · registry result, not featured evidence 36 mg capsule QD headache 15.9% vomiting 10.8% diarrhoea 6.3% NCT06440980 · Phase 1 · registry result, not featured evidence 12 mg capsule QD constipation 6% nausea 6% headache 4% NCT06440980 · Phase 1 · registry result, not featured evidence 12 mg capsule QD constipation 21% headache 19.4% nausea 17.2% NCT06440980 · Phase 1 · registry result, not featured evidence 6 mg capsule QD headache 8.7% dyspepsia 4.3% vomiting 4.3% NCT06440980 · Phase 1 · registry result, not featured evidence 6 mg capsule QD headache 12.3% nausea 9.4% dyspepsia 7.9% NCT06440980 · Phase 1 · registry result, not featured evidence 24 mg capsule QD headache 10% vomiting 6% abdominal pain 4% NCT06440980 · Phase 1 · registry result, not featured evidence 24 mg capsule QD nausea 17.1% diarrhoea 12.7% constipation 10.5% NCT06440980 · Phase 1 · registry result, not featured evidence 14.5 mg tablet QD headache 8.3% nausea 8.3% diarrhoea 6.7% NCT06440980 · Phase 1 · registry result, not featured evidence 9 mg tablet QD headache 9.7% constipation 9.1% vomiting 8.1% NCT06440980 · Phase 1 · registry result, not featured evidence 5.5 mg tablet QD headache 8.4% nausea 8.4% constipation 4.9% NCT06440980 · Phase 1 · registry result, not featured evidence 3 mg capsule QD nausea 4.3% decreased appetite 2.1% diarrhoea 2.1% NCT06440980 · Phase 1 · registry result, not featured evidence 3 mg capsule QD headache 17.6% nausea 13.8% constipation 9.5% NCT06440980 · Phase 1 · registry result, not featured evidence 2.5 mg tablet QD headache 8.1% constipation 6.2% nausea 6.2% NCT06440980 · Phase 1 · registry result, not featured evidence 1 mg capsule QD constipation 7.7% decreased appetite 1.9% eructation 1.9% NCT06440980 · Phase 1 · registry result, not featured evidence 1 mg capsule QD constipation 27% headache 15.8% nausea 6% NCT06440980 · Phase 1 · registry result, not featured evidence 0.8 mg tablet QD constipation 8.9% headache 8.9% dyspepsia 4.7% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 1) constipation 9.6% diarrhoea 1.9% eructation 1.9% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 2) abdominal pain 3.8% diarrhoea 3.8% constipation 1.9% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 3) constipation 13.5% abdominal distension 1.9% dizziness 1.9% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 4) nausea 7.8% vomiting 7.8% constipation 5.9% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 5) nausea 8.3% dyspepsia 6.3% headache 6.3% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 6) diarrhoea 5.9% abdominal pain 3.9% constipation 3.9% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 7) nausea 6.5% dyspepsia 4.3% headache 4.3% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 8) dyspepsia 6.4% headache 4.3% nausea 4.3% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 9) nausea 10.9% abdominal distension 6.5% abdominal pain 6.5% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 10) constipation 8% diarrhoea 6% dyspepsia 6% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 12) nausea 8% headache 6% diarrhoea 4% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 13) constipation 8.2% abdominal pain 4.1% diarrhoea 4.1% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 14) dizziness 12.2% headache 6.1% abdominal pain 4.1% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 15) nausea 8% constipation 4% diarrhoea 4% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 16) heart rate increased 8.9% constipation 4.4% headache 4.4% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 18) constipation 6.7% diarrhoea 6.7% nausea 4.4% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 11) dyspepsia 6% constipation 4% diarrhoea 4% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 17) nausea 13.3% headache 6.7% diarrhoea 4.4% NCT06440980 · Phase 1 · registry result, not featured evidence decreased appetite 70% (placebo 50%) diarrhoea 60% (placebo 25%) eructation 40% (placebo 0%) NCT06023095 · Phase 1 · registry result, not featured evidence nausea 80% (placebo 0%) decreased appetite 70% (placebo 50%) diarrhoea 70% (placebo 25%) NCT06023095 · Phase 1 · registry result, not featured evidence 36 mg constipation 4.5% diarrhoea 4.5% abdominal pain 0% NCT06186622 · Phase 1 · registry result, not featured evidence 36 mg abdominal pain upper 4.5% dizziness 4.5% vomiting 4.5% NCT06186622 · Phase 1 · registry result, not featured evidence 36 mg abdominal pain 0% abdominal pain upper 0% alanine aminotransferase increased 0% NCT06186622 · Phase 1 · registry result, not featured evidence 36 mg QD back pain 4.5% diarrhoea 4.5% abdominal pain 0% NCT06186622 · Phase 1 · registry result, not featured evidence 36 mg QD constipation 23.1% nausea 11.5% abdominal pain 7.7% NCT06186622 · Phase 1 · registry result, not featured evidence 36 mg abdominal pain 0% abdominal pain upper 0% alanine aminotransferase increased 0% NCT06186622 · Phase 1 · registry result, not featured evidence 36 mg QD constipation 22.2% alopecia 5.6% diarrhoea 5.6% NCT06186622 · Phase 1 · registry result, not featured evidence 36 mg QD anxiety 6.3% constipation 6.3% abdominal pain 0% NCT06186622 · Phase 1 · registry result, not featured evidence 12 mg QD alanine aminotransferase increased 3.8% aspartate aminotransferase increased 3.8% fatigue 3.8% NCT06186622 · Phase 1 · registry result, not featured evidence 12 mg QD back pain 5.3% constipation 5.3% cough 5.3% NCT06186622 · Phase 1 · registry result, not featured evidence 6 mg QD dyspepsia 7.7% nausea 7.7% diarrhoea 3.8% NCT06186622 · Phase 1 · registry result, not featured evidence 6 mg QD fatigue 15.8% eructation 10.5% headache 10.5% NCT06186622 · Phase 1 · registry result, not featured evidence 36 mg + 0.2 mg dizziness 4.8% headache 4.8% abdominal pain 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 36 mg + 0.25 mg nausea 9.1% abdominal pain 0% abdominal pain upper 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 36 mg + 20 mg decreased appetite 4.5% headache 4.5% abdominal pain 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 36 mg + 20 mg abdominal pain 0% abdominal pain upper 0% alanine aminotransferase increased 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 36 mg + 1000 mg headache 4.5% nausea 4.5% abdominal pain 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 36 mg + 20 mg abdominal pain 0% abdominal pain upper 0% alanine aminotransferase increased 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 36 mg + 0.25 mg constipation 6.3% abdominal pain 0% abdominal pain upper 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 36 mg + 20 mg abdominal pain upper 6.3% abdominal pain 0% alanine aminotransferase increased 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 36 mg + 20 mg dysmenorrhoea 6.3% abdominal pain 0% abdominal pain upper 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 24 mg QD abdominal pain 3.8% diarrhoea 3.8% headache 3.8% NCT06186622 · Phase 1 · registry result, not featured evidence 24 mg QD constipation 5.6% diarrhoea 5.6% eructation 5.6% NCT06186622 · Phase 1 · registry result, not featured evidence 20 mg + 20 mg alanine aminotransferase increased 9.1% aspartate aminotransferase increased 9.1% abdominal pain 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 20 mg + 20 mg alanine aminotransferase increased 12.5% aspartate aminotransferase increased 12.5% headache 6.3% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 3 mg QD diarrhoea 3.8% fatigue 3.8% nausea 3.8% NCT06186622 · Phase 1 · registry result, not featured evidence 3 mg QD abdominal pain 10% nausea 10% alanine aminotransferase increased 5% NCT06186622 · Phase 1 · registry result, not featured evidence 1 mg QD medication error 7.4% dysmenorrhoea 3.7% fatigue 3.7% NCT06186622 · Phase 1 · registry result, not featured evidence 1 mg + 1000 mg headache 3.7% abdominal pain 0% abdominal pain upper 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 1 mg QD eructation 15% decreased appetite 10% headache 10% NCT06186622 · Phase 1 · registry result, not featured evidence 36 mg capsule nausea 9.5% abdominal pain 4.8% constipation 4.8% NCT05841238 · Phase 1 · registry result, not featured evidence 36 mg capsule diarrhoea 4.4% abdominal pain 2.2% abdominal distension 0% NCT05841238 · Phase 1 · registry result, not featured evidence 36 mg DF capsule constipation 8.3% diarrhoea 8.3% nausea 8.3% NCT05841238 · Phase 1 · registry result, not featured evidence 36 mg EPB capsule nausea 41.7% headache 16.7% diarrhoea 8.3% NCT05841238 · Phase 1 · registry result, not featured evidence 60 mg tablet vomiting 14.3% constipation 4.8% dyspepsia 4.8% NCT05841238 · Phase 1 · registry result, not featured evidence 45 mg tablet abdominal distension 9.5% nausea 9.5% vomiting 4.8% NCT05841238 · Phase 1 · registry result, not featured evidence 37.5 mg tablet headache 19% nausea 19% constipation 9.5% NCT05841238 · Phase 1 · registry result, not featured evidence 37.5 mg tablet nausea 14.6% headache 12.2% vomiting 12.2% NCT05841238 · Phase 1 · registry result, not featured evidence 35 mg tablet dyspepsia 14.3% flatulence 14.3% nausea 14.3% NCT05841238 · Phase 1 · registry result, not featured evidence 35 mg tablet intertrigo 14.3% abdominal distension 0% abdominal pain 0% NCT05841238 · Phase 1 · registry result, not featured evidence 20 mg tablet dyspepsia 4.3% abdominal pain 2.2% diarrhoea 2.2% NCT05841238 · Phase 1 · registry result, not featured evidence 16 mg capsule diarrhoea 6.5% vomiting 2.2% abdominal distension 0% NCT05841238 · Phase 1 · registry result, not featured evidence 10 mg tablet constipation 12.2% nausea 4.1% dyspepsia 2% NCT05841238 · Phase 1 · registry result, not featured evidence 8 mg capsule dyspepsia 10.2% decreased appetite 6.1% diarrhoea 6.1% NCT05841238 · Phase 1 · registry result, not featured evidence 5 mg tablet headache 12% dyspepsia 4% abdominal pain 2% NCT05841238 · Phase 1 · registry result, not featured evidence 2.5 mg tablet headache 4% decreased appetite 2% gastrooesophageal reflux disease 2% NCT05841238 · Phase 1 · registry result, not featured evidence 2 mg capsule constipation 10% diarrhoea 2% abdominal distension 0% NCT05841238 · Phase 1 · registry result, not featured evidence 0.8 mg tablet constipation 3.8% headache 3.8% nausea 3.8% NCT05841238 · Phase 1 · registry result, not featured evidence constipation 37.5% headache 33.3% weight decreased 25% NCT05313802 · Phase 1 · registry result, not featured evidence dyspepsia 41.7% constipation 33.3% weight decreased 29.2% NCT05313802 · Phase 1 · registry result, not featured evidence constipation 25% dyspepsia 25% headache 16.7% NCT05313802 · Phase 1 · registry result, not featured evidence | 2.4 mg weeklym nausea 44.1% (placebo 17.4%) diarrhoea 31.5% (placebo 15.9%) vomiting 24.6% (placebo 6.6%) NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 show 35 more results2.4 mg diarrhoea 14.4% (placebo 7.1%) nausea 14% (placebo 4.9%) constipation 11.6% (placebo 6%) NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 2.4 mg nausea 33.5% (placebo 9.2%) diarrhoea 21.3% (placebo 11.9%) vomiting 21.3% (placebo 2.7%) NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 covid-19 20.3% (placebo 20.3%) nausea 18.1% (placebo 3.8%) diarrhoea 10.6% (placebo 4%) NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3 2.4 mg nausea 58.2% (placebo 22.1%) constipation 36.9% (placebo 24.5%) diarrhoea 36.1% (placebo 22.1%) NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 nausea 73.6% (placebo 25%) constipation 52.8% (placebo 16.7%) diarrhea 37.5% (placebo 22.9%) NCT05548647 · Phase 4 · registry result, not featured evidence · combination diarrhea 20% (placebo 22.9%) constipation 10% (placebo 16.7%) eructation 10% (placebo 6.3%) NCT05548647 · Phase 4 · registry result, not featured evidence 2.4 mg decreased appetite 19.3% (placebo 2.5%) diarrhoea 18.6% (placebo 7.4%) nausea 18% (placebo 2.5%) NCT06041217 · Phase 3 · registry result, not featured evidence 7.2 mg nausea 43.7% (placebo 13.4%) diarrhoea 27.3% (placebo 12.9%) vomiting 24.8% (placebo 7%) NCT05646706 · Phase 3 · registry result, not featured evidence nausea 37.6% (placebo 14.3%) diarrhoea 27.7% (placebo 6.1%) constipation 21.8% (placebo 16.3%) NCT04998136 · Phase 3 · registry result, not featured evidence 2.4 mg nausea 21.9% (placebo 8.9%) covid-19 18.6% (placebo 22.2%) constipation 11.9% (placebo 5.2%) NCT05064735 · Phase 3 · registry result, not featured evidence 2.4 mg covid-19 34.8% (placebo 30.4%) nausea 29% (placebo 4.3%) constipation 18.1% (placebo 0%) NCT05040971 · Phase 3 · registry result, not featured evidence 2.4 mg nausea 17.1% (placebo 2.6%) covid-19 13.7% (placebo 15.4%) diarrhoea 9.1% (placebo 3.8%) NCT04788511 · Phase 3 · registry result, not featured evidence 2.4 mg diarrhoea 26.1% (placebo 10.3%) nausea 24.1% (placebo 7.1%) upper respiratory tract infection 20.5% (placebo 20.6%) NCT04251156 · Phase 3 · registry result, not featured evidence 2.4 mg nausea 42.1% (placebo 17.9%) vomiting 36.1% (placebo 10.4%) diarrhoea 21.8% (placebo 19.4%) NCT04102189 · Phase 3 · registry result, not featured evidence 2.4 mg nausea 61.1% (placebo 22.4%) constipation 38.9% (placebo 23.5%) diarrhoea 27.8% (placebo 25.9%) NCT04074161 · Phase 3 · registry result, not featured evidence 2.4 mg nausea 53.3% (placebo 21.7%) diarrhoea 34.9% (placebo 23.7%) constipation 30.9% (placebo 11.2%) NCT03693430 · Phase 3 · registry result, not featured evidence 2.4 mg nasopharyngitis 26.6% (placebo 17.8%) constipation 26.1% (placebo 3%) nausea 17.6% (placebo 4%) NCT03811574 · Phase 3 · registry result, not featured evidence 1.7 mg nasopharyngitis 24% (placebo 17.8%) diarrhoea 22% (placebo 5.9%) constipation 19% (placebo 3%) NCT03811574 · Phase 3 · registry result, not featured evidence 30 mg/kg + 1.0 mg muscle spasms 64.3% acne 55.4% diarrhoea 44.6% NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 30 mg/kg + 2.4 mg muscle spasms 63.6% acne 52.7% diarrhoea 49.1% NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 10 mg/kg + 1.0 mg muscle spasms 57.1% diarrhoea 48.2% acne 42.9% NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 10 mg/kg + 2.4 mg muscle spasms 65.5% nausea 61.8% diarrhoea 52.7% NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 gastrointestinal side effects: constipation 57.1% gi side effects: nausea 28.6% gi side effects: vomiting 14.3% NCT05302596 · Phase 2 · registry result, not featured evidence 2.0 mg + 2.4 mg decreased appetite 87.5% (placebo 75%) nausea 87.5% (placebo 12.5%) vomiting 75% (placebo 0%) NCT04969939 · Phase 2 · registry result, not featured evidence · combination 2.0 mg + 2.4 mg nausea 62.5% (placebo 12.5%) constipation 50% (placebo 0%) vomiting 37.5% (placebo 0%) NCT04969939 · Phase 2 · registry result, not featured evidence · combination 1.0 mg + 2.4 mg decreased appetite 87.5% (placebo 75%) nausea 50% (placebo 12.5%) abdominal pain 37.5% (placebo 0%) NCT04969939 · Phase 2 · registry result, not featured evidence · combination 1.0 mg + 2.4 mg nausea 44.7% (placebo 12.5%) vomiting 31.9% (placebo 0%) constipation 25.5% (placebo 0%) NCT04969939 · Phase 2 · registry result, not featured evidence · combination 0.4 mg nausea 48% (placebo 17.6%) diarrhoea 37.3% (placebo 11.8%) constipation 23.5% (placebo 4.4%) NCT02453711 · Phase 2 · registry result, not featured evidence 0.4 mg (Fast Escalation) nausea 48.5% (placebo 17.6%) constipation 28.2% (placebo 4.4%) diarrhoea 27.2% (placebo 11.8%) NCT02453711 · Phase 2 · registry result, not featured evidence 0.3 mg nausea 41.7% (placebo 17.6%) diarrhoea 26.2% (placebo 11.8%) constipation 17.5% (placebo 4.4%) NCT02453711 · Phase 2 · registry result, not featured evidence 0.3 mg (Fast Escalation) nausea 53.9% (placebo 17.6%) diarrhoea 27.5% (placebo 11.8%) vomiting 20.6% (placebo 4.4%) NCT02453711 · Phase 2 · registry result, not featured evidence 0.2 mg nausea 43.7% (placebo 17.6%) diarrhoea 34% (placebo 11.8%) constipation 25.2% (placebo 4.4%) NCT02453711 · Phase 2 · registry result, not featured evidence 0.1 mg nausea 41.2% (placebo 17.6%) diarrhoea 24.5% (placebo 11.8%) nasopharyngitis 22.5% (placebo 11.8%) NCT02453711 · Phase 2 · registry result, not featured evidence 0.05 mg nausea 31.1% (placebo 17.6%) diarrhoea 19.4% (placebo 11.8%) nasopharyngitis 15.5% (placebo 11.8%) NCT02453711 · Phase 2 · registry result, not featured evidence nausea 58.3% (placebo 20.8%) abdominal pain 31.3% (placebo 20.8%) diarrhea 29.2% (placebo 10.4%) NCT04779697 · Phase 1 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dTrial phases differ: Phase 1 versus Phase 3.
- eThe assessment timepoint is not available for both results.
- fPopulation context differs: registered conditions differ.
- gAssessment timepoints differ: 72 weeks versus 68 weeks.
- hTrial phases differ: Phase 2 versus Phase 3.
- iAssessment timepoints differ: 36 weeks versus 104 weeks.
- jThe reported result categories differ.
- kOne study enrolled healthy volunteers and the other enrolled patients.
- lPopulation comparability has not been reviewed for these studies.
- mPopulation comparability has not been reviewed for 30 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
orforglipron
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
Semaglutide (Wegovy)
show 3 more results
show 3 more results
show 14 more results
show 13 more results
show 13 more results
show 2 more results
+ 134 further endpoints in the CSV export.
Atherosclerotic Cardiovascular Disease
Shared mechanism: GLP-1 receptor · full Atherosclerotic Cardiovascular Disease pipeline
orforglipron · Foundayo
Marketed by Eli Lilly and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2028 · NCT07223593 (registry estimate)
No aligned efficacy figure on record for this race.
Semaglutide (Wegovy)
Marketed by Novo Nordisk
NCT03574597 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 17,604 participants and a hard cardiovascular event primary endpoint. The primary endpoint was met: 569 participants receiving semaglutide versus 701 receiving placebo experienced a qualifying event, with a hazard ratio of 0.80 (95% CI 0.72–0.89; p<0.0001).
Reported efficacy
Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801 (met)
Result source: NCT03574597
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | orforglipron | Semaglutide (Wegovy) |
|---|---|---|
| LDL-C, % change | —Trial running · NCT07241390 | —Not reported |
| Non-HDL-C, % change | —Trial running · NCT07241390 | —Not reported |
| ApoB, % change | —Trial running · NCT07241390 | —Not reported |
| Lp(a), % change | —Trial running · NCT07241390 | —Not reported |
| 3-point MACE (% with event) | —Trial running · NCT07241390 | —Not reported |
LDL-C, % change
- orforglipron
- —Trial running · NCT07241390
- Semaglutide (Wegovy)
- —Not reported
Non-HDL-C, % change
- orforglipron
- —Trial running · NCT07241390
- Semaglutide (Wegovy)
- —Not reported
ApoB, % change
- orforglipron
- —Trial running · NCT07241390
- Semaglutide (Wegovy)
- —Not reported
Lp(a), % change
- orforglipron
- —Trial running · NCT07241390
- Semaglutide (Wegovy)
- —Not reported
3-point MACE (% with event)
- orforglipron
- —Trial running · NCT07241390
- Semaglutide (Wegovy)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
orforglipron: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: orforglipron's landscape · Semaglutide (Wegovy)'s landscape